 |
[Alpha Biz=(Chicago) Reporter Paul Lee] On the 31st, PCL, a company specializing in in vitro diagnosis, announced that it decided to increase the paid-in capital in the form of a general public offering of disqualified shares after allocating shareholders worth 36.036 billion won.
It is a bequest to raise funds for operation and debt repayment. Specifically, the company plans to execute 1 billion won in development of smart on-site rapid diagnostic devices (POCT) △ 4 billion won in development of diagnostic reagents △ 10 billion won in introduction of new diagnostic reagents △ 5 billion won in introduction of new equipment △ 6.036 billion won in domestic and overseas sales and marketing △ 6 billion won in repayment of loans from Korea Development Bank △ 4 billion won in repayment of subsidiary Mcurex loans.
The subscription date is September 4th to 5th and the payment date is September 12th. The new shares issued are 5.2 million ordinary shares and the planned issuance price is 6,930 won (finalized on August 30). It is about 34% lower than the previous day's PCL closing price of 10,480 won. PCL also announced no symptoms immediately after the bequest. The decision was made to pay two new shares per common stock held by PCL shareholders free of charge. With this no certificate, PCL will issue 34,352,472 new shares. The base date for the allocation of new shares is September 15 and the listing date is October 11.
There are more bio companies that have decided this month to 'no evidence after bequest in the form of a general public offering after shareholder allocation'. Kleenomics, a genetic analysis-based diagnostic company, will be duty-free to allocate 0.5 shares per common share and 0.49999869 shares per preferred share after a bequest worth 44.6 billion won.
AlphaBIZ 폴 리(hoondork1977@alphabiz.co.kr)
